Molecular alterations in RCC tumors have been extensively studied in the last decade, especially in ccRCC but neither identified mutations (e.g.,: VHL, BAP1, PBRM1, SETD2, KDM5C, MTOR) nor transcriptome-based ccRCC tumor sub-classification have straightforward clinical relevance [47,48]. Here, SETD2 is linked to renal cell carcinoma.